HOME
Latest news:

- VCN Biosciences to present clinical data on systemic administration of VCN-01 in pancreatic cancer patients at 28th EORTC-NCI-AACR SYMPOSIUM on Molecular Targets & Cancer Therapeutics.
> Read more
...........................................

- VCN Biosciences initiates Part II of its on-going Phase 1 clinical trial with VCN-01 in pancreatic cancer patients.
> Read more
...........................................

- VCN Biosciences announces that MINECO has granted funding for the project Cure4RB to clinically develop its lead candidate VCN-01 for the treatment of retinoblastoma.
> Read more

 

Vcn Biosciences

VCN Biosciences SL is a privately-owned company focused in the development of new therapeutic approaches for tumors that lack effective treatment. The company uses an oncolytic adenovirus technology platform to design highly selective and efficient agents that replicate and self-amplify exclusively in tumor cells. The selectivity of VCN oncolytic adenoviruses allows their systemic administration, which is especially relevant for the treatment of disseminated cancer. Contrary to chemotherapy, the ability of oncolytic virus to self-amplify in tumor cells results in an effective dose increase with time. These properties highlight VCN candidates as promising alternatives for the treatment of refractory tumors such as pancreatic adenocarcinomas, which is the current tumor target for VCN-01.